How should medical oncologists and dermatologists communicate about patients with at least Stage IIB/III cutaneous melanoma regarding neoadjuvant immunotherapy?

Only melanoma patients with stage III or resectable stage IV disease should be treated with standard-of-care neoadjuvant immunotherapy.

These patients should see a medical oncologist first (and no longer last, as is the current process). I would recommend that the schedulers at your institution be e...